Serveur d'exploration sur la maladie de Parkinson

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP‐treated common marmosets

Identifieur interne : 002D71 ( Main/Curation ); précédent : 002D70; suivant : 002D72

Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP‐treated common marmosets

Auteurs : Louisa Clare Johnston [Royaume-Uni] ; Michael John Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; Andrew Christopher Mccreary [Pays-Bas] ; Peter Jenner [Royaume-Uni]

Source :

RBID : ISTEX:2113A8D24FCE723BD8E69F9D2D48F046F73F105C

English descriptors

Abstract

Long‐acting full dopamine D2 agonists produce less dyskinesia in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated primates and in Parkinson's disease than effective antiparkinsonian doses of levodopa. They do not however, prevent priming for dyskinesia expression on subsequent levodopa exposure. In contrast, the effects of partial D2 receptor agonists on dyskinesia are unclear. We now examine the ability of the partial D2 agonist pardoprunox (SLV308) to improve motor function and its propensity to prime for dyskinesia in drug naïve, MPTP‐treated common marmosets. Previously, drug naïve, MPTP‐treated common marmosets were treated with equivalent doses of either pardoprunox (SLV308) (0.1 mg/kg po), ropinirole (0.18 mg/kg po), or levodopa (10 mg/kg po BID) for 28 days. All treatments induced a similar reduction of motor disability. Dyskinesia induced by levodopa was of greater intensity than that following administration of either pardoprunox (SLV308) or ropinirole. Administration of pardoprunox (SLV308) resulted in dyskinesia that was less intense and of shorter duration than either ropinirole or levodopa. At the end of drug treatment, acute challenge with levodopa resulted in the expression of marked dyskinesia in animals that had previously received chronic levodopa or ropinirole treatment. However, animals previously treated with pardoprunox (SLV308) showed only mild dyskinesia in response to the levodopa challenge. These results suggest that the partial D2 agonist pardoprunox (SLV308) is less likely to prime for dyskinesia or to lead to the expression of dyskinesia than either levodopa or full dopamine agonists. © 2010 Movement Disorder Society

Url:
DOI: 10.1002/mds.23249

Links toward previous steps (curation, corpus...)


Links to Exploration step

ISTEX:2113A8D24FCE723BD8E69F9D2D48F046F73F105C

Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP‐treated common marmosets</title>
<author>
<name sortKey="Johnston, Louisa Clare" sort="Johnston, Louisa Clare" uniqKey="Johnston L" first="Louisa Clare" last="Johnston">Louisa Clare Johnston</name>
<affiliation wicri:level="1">
<mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Jackson, Michael John" sort="Jackson, Michael John" uniqKey="Jackson M" first="Michael John" last="Jackson">Michael John Jackson</name>
<affiliation wicri:level="1">
<mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name>
<affiliation wicri:level="1">
<mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Mccreary, Andrew Christopher" sort="Mccreary, Andrew Christopher" uniqKey="Mccreary A" first="Andrew Christopher" last="Mccreary">Andrew Christopher Mccreary</name>
<affiliation wicri:level="1">
<mods:affiliation>Solvay Pharmaceuticals Research Laboratories, Weesp, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals Research Laboratories, Weesp</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
<affiliation wicri:level="1">
<mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2113A8D24FCE723BD8E69F9D2D48F046F73F105C</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.23249</idno>
<idno type="url">https://api.istex.fr/document/2113A8D24FCE723BD8E69F9D2D48F046F73F105C/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">003171</idno>
<idno type="wicri:Area/Main/Curation">002D71</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP‐treated common marmosets</title>
<author>
<name sortKey="Johnston, Louisa Clare" sort="Johnston, Louisa Clare" uniqKey="Johnston L" first="Louisa Clare" last="Johnston">Louisa Clare Johnston</name>
<affiliation wicri:level="1">
<mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Jackson, Michael John" sort="Jackson, Michael John" uniqKey="Jackson M" first="Michael John" last="Jackson">Michael John Jackson</name>
<affiliation wicri:level="1">
<mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name>
<affiliation wicri:level="1">
<mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Mccreary, Andrew Christopher" sort="Mccreary, Andrew Christopher" uniqKey="Mccreary A" first="Andrew Christopher" last="Mccreary">Andrew Christopher Mccreary</name>
<affiliation wicri:level="1">
<mods:affiliation>Solvay Pharmaceuticals Research Laboratories, Weesp, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Solvay Pharmaceuticals Research Laboratories, Weesp</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
<affiliation wicri:level="1">
<mods:affiliation>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College, London</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-10-15">2010-10-15</date>
<biblScope unit="volume">25</biblScope>
<biblScope unit="issue">13</biblScope>
<biblScope unit="page" from="2059">2059</biblScope>
<biblScope unit="page" to="2066">2066</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">2113A8D24FCE723BD8E69F9D2D48F046F73F105C</idno>
<idno type="DOI">10.1002/mds.23249</idno>
<idno type="ArticleID">MDS23249</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>MPTP</term>
<term>Parkinson's disease</term>
<term>dyskinesia</term>
<term>levodopa</term>
<term>pardoprunox (SLV308)</term>
<term>partial agonist</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Long‐acting full dopamine D2 agonists produce less dyskinesia in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)‐treated primates and in Parkinson's disease than effective antiparkinsonian doses of levodopa. They do not however, prevent priming for dyskinesia expression on subsequent levodopa exposure. In contrast, the effects of partial D2 receptor agonists on dyskinesia are unclear. We now examine the ability of the partial D2 agonist pardoprunox (SLV308) to improve motor function and its propensity to prime for dyskinesia in drug naïve, MPTP‐treated common marmosets. Previously, drug naïve, MPTP‐treated common marmosets were treated with equivalent doses of either pardoprunox (SLV308) (0.1 mg/kg po), ropinirole (0.18 mg/kg po), or levodopa (10 mg/kg po BID) for 28 days. All treatments induced a similar reduction of motor disability. Dyskinesia induced by levodopa was of greater intensity than that following administration of either pardoprunox (SLV308) or ropinirole. Administration of pardoprunox (SLV308) resulted in dyskinesia that was less intense and of shorter duration than either ropinirole or levodopa. At the end of drug treatment, acute challenge with levodopa resulted in the expression of marked dyskinesia in animals that had previously received chronic levodopa or ropinirole treatment. However, animals previously treated with pardoprunox (SLV308) showed only mild dyskinesia in response to the levodopa challenge. These results suggest that the partial D2 agonist pardoprunox (SLV308) is less likely to prime for dyskinesia or to lead to the expression of dyskinesia than either levodopa or full dopamine agonists. © 2010 Movement Disorder Society</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D71 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002D71 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     ISTEX:2113A8D24FCE723BD8E69F9D2D48F046F73F105C
   |texte=   Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP‐treated common marmosets
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024